# A Study to Look at How Safe NNC0268-0965 is in People With Type 2 Diabetes

> **NCT04136067** · PHASE1 · COMPLETED · sponsor: **Novo Nordisk A/S** · enrollment: 36 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** NNC0268-0965
- **DRUG:** insulin glargine

## Key facts

- **NCT ID:** NCT04136067
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-10-29
- **Primary completion:** 2020-08-23
- **Final completion:** 2020-08-23
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2022-09-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04136067

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04136067, "A Study to Look at How Safe NNC0268-0965 is in People With Type 2 Diabetes". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT04136067. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*